Confronto
Cerebrolysin vs. Selank
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
96889-70-6
129954-34-3
Peso molecolare
nessun dato
751.85 g/mol
Emivita
nessun dato
0.3 h
Sequenza
nessun dato
Thr-Lys-Pro-Arg-Pro-Gly-ProMeccanismo d'azione
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
2
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cerebrolysin and Selank?
- Cerebrolysin is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cerebrolysin or Selank?
- The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cerebrolysin and Selank in Germany and the United States?
- Germania: Cerebrolysin — Non chiaro, Selank — Non approvato. Stati Uniti: Cerebrolysin — Non approvato, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.